Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423899 | 0.95 | AKR1C3 (0.37) | AKR1C3AKR1C2LMNATSHRELANE | |
| SCHEMBL6423814 | 0.93 | AKR1C3 (0.39) | AKR1C3AKR1C2LMNATSHRELANE | |
| SCHEMBL6426830 | 0.92 | ALDH1A1 (0.36) | AKR1C3AKR1C2LMNAELANENOTUM | |
| SCHEMBL6428308 | 0.89 | AKR1C3 (0.40) | AKR1C3AKR1C2LMNATSHRELANE | |
| SCHEMBL6428602 | 0.89 | AKR1C3 (0.34) | AKR1C3AKR1C2KMT2A | |
| SCHEMBL6425604 | 0.87 | ALDH1A1 (0.38) | AKR1C3AKR1C2LMNAELANENOTUM | |
| SCHEMBL6428613 | 0.87 | AKR1C3 (0.39) | AKR1C3AKR1C2LMNATSHRELANE | |
| SCHEMBL6424231 | 0.87 | TSHR (0.34) | AKR1C3AKR1C2LMNATSHRNOTUM | |
| SCHEMBL6465125 | 0.87 | AKR1C3 (0.33) | AKR1C3AKR1C2TSHRNOTUMKMT2A | |
| SCHEMBL6424850 | 0.87 | AKR1C3 (0.42) | AKR1C3AKR1C2LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885LMNA 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.